ArticleNPJ precision oncology2025
Integrative multiomics analysis of platelet-related genes unveils molecular subtypes and prognostic signatures in acute myeloid leukemia.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Acute myeloid leukemia (AML) remains challenging due to molecular heterogeneity and limited prognostic models integrating tumor microenvironment dynamics. While thrombocytopenia correlates with poor outcomes, the roles of platelet-related genes (PRGs) in AML pathogenesis are unclear. We integrated multiomics data to analyze platelet-clinicopathological associations, identify PRGs via weighted gene coexpression network analysis, and define molecular subtypes through unsupervised clustering. A machine learning-derived PRGScore model was developed and validated. Immune features were assessed using CIBERSORT, and drug responses via ex vivo profiling. The results showed that low platelet counts predicted a poor prognosis and were inversely correlated with blast proportions, suggesting suppression of leukemia-mediated megakaryopoiesis. Platelet recovery is linked to inflammatory and coagulation pathways. We identified 22 key PRGs that were downregulated in AML and enriched in immunomodulatory pathways. Unsupervised clustering stratified AML into three PRG-based subtypes: C1 (low PRGs/platelets, best survival), C2 (intermediate), and C3 (high PRGs/platelets, worst survival). C1 exhibited cytotoxic T-cell enrichment, reduced immune checkpoint expression, a high proportion of blasts and increased proliferative activity. C3 was characterized by myeloid immunosuppression, elevated checkpoint levels, and the activation of chemoresistance pathways. The PRGScore model demonstrated robust prognostic accuracy across the 10 cohorts. Patients with a high PRGScore had a significantly worse prognosis and sensitivity to immune checkpoint inhibitors, whereas patients with a low PRGScore had a better response to cytarabine and venetoclax. This study establishes PRGs as key regulators of AML biology and prognosis, bridging platelet dynamics, immune interactions, and machine learning. The PRGScore framework advances precision medicine through risk stratification, therapeutic targeting, and biomarker discovery.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.